[CELG] Celgene Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 78.56 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 118.93 Change: 1.06 (0.9%)
Ext. hours: Change: 0 (0%)

chart CELG

Refresh chart

Strongest Trends Summary For CELG

CELG is in the medium-term up 9% in 8 months and up 19% in 1 year and up 24% in 2 years. In the long-term up 1957% in 27 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding774.6 M EPS3.09 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.91% Sales Growth - Q/Q9.47% P/E39.6
P/E To EPS Growth P/S9.32 P/BV12.43 Price/Cash Per Share10.49
Price/Free Cash Flow29.58 ROA12.38% ROE34.76% ROI15.22%
Current Ratio3.34 Quick Ratio3.2 Long Term Debt/Equity0.9 Debt Ratio0.47
Gross Margin95.19% Operating Margin31.72% Net Profit Margin26.08% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-951.3 M Cash From Investing Activities239.7 M Cash From Operating Activities1.14 B Gross Profit2.18 B
Net Profit356.2 M Operating Profit412.4 M Total Assets17.75 B Total Current Assets9.88 B
Total Current Liabilities2.96 B Total Debt7.62 B Total Liabilities11.42 B Total Revenue2.28 B
Technical Data
High 52 week100.95 Low 52 week59.21 Last close100.95 Last change0.56%
RSI64.77 Average true range1.09 Beta1.07 Volume2.51 M
Simple moving average 20 days1.69% Simple moving average 50 days3.66% Simple moving average 200 days8.8%
Performance Data
Performance Week2.09% Performance Month2.61% Performance Quart11.09% Performance Half6.77%
Performance Year22.25% Performance Year-to-date57.51% Volatility daily0.65% Volatility weekly1.44%
Volatility monthly2.96% Volatility yearly10.25% Relative Volume218.43% Average Volume3.53 M
New High New Low

News

2020-05-27 10:00:53 | Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?

2020-05-27 08:00:05 | The No. 1 Pharma Is Poised For Double-Digit Growth — Is BMY Stock A Buy?

2020-05-19 08:00:53 | Biotech Giant Amgen Is Nearing A Breakout, But Is AMGN Stock A Buy?

2020-05-07 04:46:25 | Stocks - Peloton, PayPal Surge in Premarket on Boost From Lockdowns

2020-05-01 08:00:53 | Biotech Amgen Is Tackling Coronavirus From Two Sides — But Is It A Buy?

2020-04-22 08:00:05 | Is The No. 1 Pharmaceutical Stock A Buy As It Approaches A Breakout?

2020-03-26 13:02:05 | The No. 1 Pharma Company Nabbed A Key Approval — But Is It A Buy?

2020-03-13 16:22:11 | Celgene Corporation -- Moody's withdraws Celgene's ratings

2020-03-12 09:00:05 | Is The No. 1 Pharma Stock A Buy Following Its Massive Acquisition?

2020-03-05 08:00:05 | The No. 1 Pharma Stock Just Topped A Buy Point — Is BMY Stock A Buy?

2020-02-28 10:33:39 | GAMCO Investors Exits Viacom, Spark Therapeutics

2020-02-26 14:22:32 | Ronald Muhlenkamp's Firm Exits Celgene, Trims Gilead Position

2020-02-26 09:00:05 | Bristol-Myers Stock Retains Its Breakout — Is It Time To Add Shares?

2020-02-25 11:26:49 | Pioneer Investments Cuts Linde, McDonald's

2020-02-21 12:13:26 | Ronald Muhlenkamp's Firm Buys 3 Stocks in 4th Quarter

2020-02-20 12:37:50 | David Abrams Buys 2 Stocks in 4th Quarter

2020-02-19 12:09:47 | David Rolfe's Firm Cuts Apple, Visa

2020-02-07 08:00:05 | Bristol-Myers Posts Bullish Growth — But Is It Time To Add BMY Stock?

2020-02-04 14:32:23 | Eaton Vance Exits Celgene, Trims Amgen Position

2020-01-28 05:26:18 | Acceleron stock soars on lung drug trial data

2020-01-14 13:02:10 | Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company

2020-01-14 13:02:07 | Celgene Corporation -- Moody's announces completion of a periodic review of ratings of Celgene Corporation

2020-01-07 07:10:00 | NASDAQ: CELG Investor Notice: Update in Lawsuit against Celgene Corporation announced by Shareholders Foundation

2019-12-30 10:35:59 | An Unusual Investment With 125% Upside

2019-12-16 07:30:10 | NexImmune Appoints Sol Barer as Chairman of the Board of Directors

2019-12-12 13:06:10 | Bristol-Myers business development head Biondi departs

2019-12-10 10:10:03 | Biotech ETFs Hit New Highs on Deal Activities

2019-12-09 09:02:00 | Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise

2019-12-07 14:00:00 | Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

2019-12-06 16:30:40 | Bluebird, Celgene Cancer Therapy Gets Boost From New Study

2019-12-06 15:30:12 | Bristol-Myers Squibb Company -- Moody's upgrades Celgene to A3

2019-12-04 08:00:05 | Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?

2019-12-03 17:09:10 | $50M deal could expand NanoString Technologies diagnostic test into more markets

2019-11-26 03:09:00 | Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

2019-11-24 22:32:29 | Here is the 17th Most Popular Stock Among 752 Hedge Funds

2019-11-24 16:19:59 | The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

2019-11-22 09:00:05 | Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?

2019-11-21 17:58:10 | Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal

2019-11-21 17:20:00 | Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut

2019-11-21 16:28:35 | Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy

2019-11-21 09:40:02 | Biotech ETF BBH Hits New 52-Week High

2019-11-21 06:41:02 | Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

2019-11-21 06:21:00 | Amgen Completes Acquisition Of Otezla® apremilast

2019-11-21 04:37:00 | Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain

2019-11-20 16:45:00 | An All or Nothing Bet on 3 Drugs in Celgene’s Pipeline

2019-11-20 16:36:00 | Bristol-Myers Squibb completes $74 billion acquisition of Celgene

2019-11-20 16:33:00 | At Long Last, Bristol-Myers Buys Celgene

2019-11-20 16:18:00 | Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb

2019-11-20 09:40:02 | Top Ranked Growth Stocks to Buy for November 20th

2019-11-20 09:31:02 | Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More